Pfizer vaccine

Companies, In Europe 30th May 2023

Pfizer agrees to cut COVID vaccine orders with EU due to falling demand

Bankinter | Pfizer and the EU have agreed to reduce the number of doses to be delivered by an undisclosed number and, to delay the validity of the contract to 2026. The reason is the drop in demand for vaccines and booster doses and that several countries have destroyed vaccines after their expiration date. The initial contract is dated May 2021 and contemplated the acquisition of 900M doses and an…

World economy 13th November 2020

Pfizer’s Vaccine Breakthrough Sweet Nectar For Corporate Bonds

Mondher Bettaieb Loriot / Claudia Fontanive-Wyss (Vontobel AM) | The recovery takes hold now that a Covid-19 vaccine is on the immediate horizon. Pfizer has announced that they, together with BIoNTech, are the first drugs-makers to achieve credible positive readings on the effectiveness of their Covid-19 vaccine trials. The recovery stage is generally the sweet spot for corporate bonds and credit spreads as corporates further increase cash flows, act for the benefit of bondholders and, in the end, reduce leverage.